ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008.

Business Wire › November 14, 2008

Linked as:

Extract

ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008.

Novel Oral Anticoagulant Promises Potential Benefits over Leading Treatment

NEW ORLEANS -- ARYx Therapeutics (NASDAQ:ARYX) announced today that clinical data for ATI-5923, a novel vitamin K epoxide reductase (VKOR) inhibitor in Phase 2/3 development for the treatment of patients at risk of forming dangerous blood clots, were presented this week at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA. The data featured in these presentations indicate that ATI-5923 has potential advantages over the l...

See the full content of this document